We serve Chemical Name:Ethyl 7-amino-4-hydroxy-2-naphthoate CAS:945034-40-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Ethyl 7-amino-4-hydroxy-2-naphthoate
CAS.NO:945034-40-2
Synonyms:ethyl 7-amino-4-hydroxynaphthalene-2-carboxylate
Molecular Formula:C13H13NO3
Molecular Weight:231.24700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:72.55000
Exact Mass:231.09000
LogP:2.88550
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like ethyl 7-amino-4-hydroxynaphthalene-2-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 7-amino-4-hydroxynaphthalene-2-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 7-amino-4-hydroxynaphthalene-2-carboxylate Use and application,ethyl 7-amino-4-hydroxynaphthalene-2-carboxylate technical grade,usp/ep/jp grade.
Related News: Beijing will strengthen its monitoring of overseas drug market and collect global prices for imported medicines, Friday��s guideline said. Ethyl 7-amino-4-hydroxy-2-naphthoate manufacturer Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. Ethyl 7-amino-4-hydroxy-2-naphthoate supplier In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. Ethyl 7-amino-4-hydroxy-2-naphthoate vendor What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. Ethyl 7-amino-4-hydroxy-2-naphthoate factory The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed.
